Naphyrone

NRG - 1, Energy1

What is it?
Naphyrone, a white crystalline powder often sold under brand names like NRG-1 and Energy1, is a stimulant drug with effects similar to recently controlled drugs like mephedrone. This drug is chemically related to pyrovalerone which used to be prescribed to treat lethargy and fatigue, but was discontinued because of concerns over potential for misuse. Pyrovalerone is already a Class C drug.

Prevalence and use
As with all the new drugs which have recently come onto the market, there are no figures for the numbers of users, although on the basis of internet search data, it seems that there has been a spike of interest in the drug since mephedrone was controlled.

Naphyrone has been selling online for about £12 - £15 a gram – and up to now marketed under false claims that it is ‘plant food’, ‘pond cleaner’ etc in order to circumvent various controls on medicines.

The drug is consumed either by sniffing the powder or swallowing it wrapped in a cigarette paper, a technique known as ‘bombing’.

Head shops and online legal high sellers often claim that naphyrone is the main ingredient in products labelled as NRG1 – one of the first ‘legal highs’ to be marketed as a ‘new legal alternative’ to mephedrone. However, separate tests of NRG1 products carried out by police, academics and drug user forums in summer 2010 found that the majority of NRG1 batches actually contained a series of recently banned Class B drugs including mephedrone and MDPV.

The law
On 7 July 2010, the Advisory Council on the Misuse of Drugs (ACMD) recommended that the government should control Naphyrone as a Class B drug under the Misuse of Drug Act, in line with mephedrone and similar stimulant drugs including amphetamine.

On 23 July 2010, legislation was passed in parliament that made Naphyrone a Class B drug in line with the ACMD’s recommendation. As a result, maximum penalties for possession are 5 years imprisonment plus a fine and for supply are 14 years imprisonment and a fine.

Effects/risks
The drug is more toxic than chemically similar drugs like mephedrone – in other words, a user could overdose on this drug more easily. This appears to be recognised by some sellers who recommend users take far smaller doses than when using say mephedrone or ecstasy.

As with all drugs of this sort, the main health risks are associated with the heart and its associated systems. Users also run the risk of amphetamine-like psychosis and dependence. On internet sites
Other Sources of information

Local organisations that offer Assessment & Treatment options for people with addictions:

SMART – Substance Misuse Assessment & Referral Team Poole
- Tel 01202 735777

BEAT – Bournemouth Engagement and Assessment Team - Tel 01202 558855

YADAS – Tel 01202 741414
www.edasuk.org/treatment/poole/poole-yadas/

REACH YP – Tel 0800 0434656
www.edasuk.org/treatment/dorset/sh/

ADDACTION – Tel 01202 558855
www.addaction.org.uk

EDP – Tel 01305 571264 - email info@edp.org.uk

National organisations that offer treatment, advice, information & support for people with addictions:

Alcohol Change –
Tel 020 3907 8480
www.alcoholchange.org.uk/

FRANK – Tel 0300 1236600
Text 82111
www.talktofrank.com/

Contact us: Helpline 01202 733322 (Weekdays 8.30am to 4.30pm, 24-hour answer phone)
Email: admin@edasuk.org
EDAS Head Office - 56 Ashley Road, Parkstone, Poole BH14 9BN

Statement
Our information and research is designed to help you make informed choices about the services that we provide. From time to time, for illustrative purposes, we may make reference to commonly available products (such as relaxation CDs and popular self-help books). We do not endorse or advertise the use of any specific product.

Disclaimer:
While we make every effort to use up-to-date and reliable sources, we cannot accept liability for errors in the sources that we use and also cannot guarantee to find all the information relevant to your enquiry or request. All responsibility for interpretation of and action upon that information rests with you. This information and advice is offered on the understanding that if you intend to support your treatment with complementary or alternative approaches then it is advisable to consult your GP to ensure that they have a complete understanding of your situation and the complementary or alternative approach that you are considering.

ID: ED-DS-21112011v2
Literature search completed: Drugscope - October 2012
Sheet published: October 2012
Review Date: October 2013

This organisation has been certified as a producer of reliable health and social care information.
www.theinformationstandard.org